source
- Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerInhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.BioSpace · 39m ago↗ source
- Summit and Akeso's ivonescimab beats Merck's Keytruda in Chinese NSCLC trialSummit Therapeutics and Akeso reported that their bispecific PD-1/VEGF antibody ivonescimab outperformed Merck's Keytruda in a Phase 3 HARMONi-2 trial conducted in China. The study enrolled first‑l…